350 related articles for article (PubMed ID: 15076168)
1. Combined blockade of AT1-receptors and ACE synergistically potentiates antihypertensive effects in SHR.
Raasch W; Jöhren O; Schwartz S; Gieselberg A; Dominiak P
J Hypertens; 2004 Mar; 22(3):611-8. PubMed ID: 15076168
[TBL] [Abstract][Full Text] [Related]
2. Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats.
Paull JR; Widdop RE
J Hypertens; 2001 Aug; 19(8):1393-402. PubMed ID: 11518847
[TBL] [Abstract][Full Text] [Related]
3. Effects of candesartan cilexetil and enalapril on structural alterations and endothelial function in small resistance arteries of spontaneously hypertensive rats.
Rizzoni D; Porteri E; Bettoni G; Piccoli A; Castellano M; Muiesan ML; Pasini G; Guelfi D; Rosei EA
J Cardiovasc Pharmacol; 1998 Nov; 32(5):798-806. PubMed ID: 9821855
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular effects of combination of perindopril, candesartan, and amlodipine in hypertensive rats.
Kim S; Zhan Y; Izumi Y; Iwao H
Hypertension; 2000 Mar; 35(3):769-74. PubMed ID: 10720593
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular status following combined angiotensin-converting enzyme and AT1 receptor inhibition in conscious spontaneously hypertensive rats.
Duke LM; Paull JR; Widdop RE
Clin Exp Pharmacol Physiol; 2003; 30(5-6):317-23. PubMed ID: 12859420
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats.
Wada T; Inada Y; Ojima M; Sanada T; Shibouta Y; Nishikawa K
Hypertens Res; 1996 Jun; 19(2):75-81. PubMed ID: 10968199
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action.
Inada Y; Ojima M; Kanagawa R; Misumi Y; Nishikawa K; Naka T
J Hum Hypertens; 1999 Jan; 13 Suppl 1():S75-80. PubMed ID: 10076925
[TBL] [Abstract][Full Text] [Related]
8. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
Baumgart P; Reismann J; Pohlmeyer H; Düsing R
Dtsch Med Wochenschr; 2001 May; 126(19):547-50. PubMed ID: 11402910
[TBL] [Abstract][Full Text] [Related]
9. Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension.
Melian EB; Jarvis B
Drugs; 2002; 62(5):787-816. PubMed ID: 11929332
[TBL] [Abstract][Full Text] [Related]
10. A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators.
Asmar R; Lacourcière Y
J Hypertens; 2000 Nov; 18(11):1683-90. PubMed ID: 11081784
[TBL] [Abstract][Full Text] [Related]
11. Regional hemodynamic effects of candesartan cilexetil (TCV-116), an angiotensin II AT1-receptor antagonist, in conscious spontaneously hypertensive rats.
Kanagawa R; Wada T; Sanada T; Ojima M; Inada Y
Jpn J Pharmacol; 1997 Mar; 73(3):185-90. PubMed ID: 9127812
[TBL] [Abstract][Full Text] [Related]
12. High-dose, not low-dose insulin increases the vasoconstrictor effect of norepinephrine in spontaneously hypertensive rats: effects of antihypertensive treatment.
Rizzoni D; Porteri E; Piccoli A; Castellano M; Pasini G; Guelfi D; Muiesan ML; Rosei EA
J Vasc Res; 1999; 36(5):393-403. PubMed ID: 10559680
[TBL] [Abstract][Full Text] [Related]
13. Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke-prone spontaneously hypertensive rats.
Gohlke P; Kuwer I; Schnell A; Amann K; Mall G; Unger T
Hypertension; 1997 Jan; 29(1 Pt 2):478-82. PubMed ID: 9039145
[TBL] [Abstract][Full Text] [Related]
14. Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats.
Inada Y; Wada T; Ojima M; Sanada T; Shibouta Y; Kanagawa R; Ishimura Y; Fujisawa Y; Nishikawa K
Clin Exp Hypertens; 1997 Oct; 19(7):1079-99. PubMed ID: 9310205
[TBL] [Abstract][Full Text] [Related]
15. Candesartan cilexetil: an update of its use in essential hypertension.
Easthope SE; Jarvis B
Drugs; 2002; 62(8):1253-87. PubMed ID: 12010090
[TBL] [Abstract][Full Text] [Related]
16. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
Fridman K; Andersson OK; Wysocki M; Friberg P; Sunzel M
Eur J Clin Pharmacol; 1998 Sep; 54(7):497-501. PubMed ID: 9832289
[TBL] [Abstract][Full Text] [Related]
17. A multicentre, 12-week study of imidapril and candesartan cilexetil in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.
Palma-Gamiz JL; Pêgo M; Marquez E; Pujol M; Olivan J; Alegría E; Sagastagoitia-Gorostiza JD; Gonzalez-Juanatey JR
Clin Drug Investig; 2007; 27(6):407-17. PubMed ID: 17506591
[TBL] [Abstract][Full Text] [Related]
18. [Candesartan cilexetil: pharmacological properties and protective effects against organ damage of a novel nonpeptide angiotensin II-receptor antagonist].
Inada Y; Naka T
Nihon Yakurigaku Zasshi; 2000 Mar; 115(3):151-60. PubMed ID: 10876800
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. ACTION Study Investigators.
Weir MR; Weber MA; Neutel JM; Vendetti J; Michelson EL; Wang RY
Am J Hypertens; 2001 Jun; 14(6 Pt 1):567-72. PubMed ID: 11411737
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide.
Malmqvist K; Kahan T; Dahl M
Am J Hypertens; 2000 May; 13(5 Pt 1):504-11. PubMed ID: 10826401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
